Schistosomiasis, caused by trematode blood flukes of the genus Schistosoma, is the second most prevalent disease after malaria in the tropical and subtropical world. Among five schistosome species, Schistosoma japonicum is the most serious, mainly because of its high egg output [1]. This parasite is mainly endemic in mainland China, the Philippines, and Indonesia. Advanced schistosomiasis, due to either an infection without chemotherapy or repeated infections over time, is the most serious form of schistosomiasis and is usually characterized by periportal liver fibrosis, spleen enlargement and congestion, portal hypertension, and other serious consequences [2]. The suffering for an advanced patient caused by schistosomes could last for a lifetime, as the associated pathological changes on the host, if not properly treated, could develop toward a more serious condition. In addition, S. japonicum in humans has been estimated to be able to live for an average of 4.5 years [3]. Prolonged survival of the parasite to as long as about 47 years has been seen in an American who emigrated from the Philippines and continued to show active eggs in rectal biopsies [4]. These eggs can continue to produce damages to organs where they are deposited. Therefore, the treatment of the disease usually includes both anti-schistosome treatment and symptomatic therapy. The former is based on fecal examinations and serological tests, which are usually negative in most cases [5], or endoscopic examination. The etiological treatment is comparatively easier when without any serious complication, and therefore, much more attention and financial aids are going to the latter. In the Zhejiang province of China for example, in 2003 there remained 1,187 advanced cases who still needed medical assistance, although the disease there had been interrupted a decade ago [6]. Such a looming problem has been suggested to exist for perhaps as long as another half century in China [7]. Fortunately, with the economic development and well-improved standards of living over the last decades in China, in 2004 the government of China redefined schistosomiasis control, together with the control of HIV/AIDS and tuberculosis, as one of its highest priorities in communicable disease control [8]. As one main part of the integrated control measures, the project for treatment of advanced schistosomiasis has been initiated across the endemic regions of China. Box 1 lists a series of regulations on that aspect made by the government. The main point of this is that a screening system for advanced schistosomiasis among local residents will be set up in each endemic county and, if a farmer is diagnosed with advanced schistosomiasis (see Box 2 for the diagnosis criteria), the involved medical expense will be mostly covered by different levels of government. Figure 1 shows the numbers of advanced cases and newly found cases in each province and, as the consequence of the project, the increasingly rising coverage rate of advanced cases [9]. The direct or long-term estimated benefit from this project, as estimated by the work [10], would be quite considerable. Here we presented a case observed in a nonendemic area within the Anhui Province of China to point out the demerit of the ongoing project and raise some aspects yet to improve. This follow-up investigation was approved by an ethics committee in both the Anhui Institute of Parasitic Diseases and Soochow University. A consent form was obtained from the patient, and she gave consent to have her case details published. Open in a separate window Figure 1 Numbers of advanced schistosomiasis japonica in China. (A) In each province by 2008; (B) in each province by 2003 and new cases found from 2004 to 2008; and (C) the coverage rates of the aid-project in the cases at the levels of nation or province (Anhui) over 2004 to 2008.
Read full abstract